AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,172.00p
   
  • Change Today:
    -74.00p
  • 52 Week High: 12,370.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.24m
  • Volume: 1,412,796
  • Market Cap: £188,695m
  • RiskGrade: 123

AstraZeneca, Daiichi's Enhertu hits trial targets

By Frank Prenesti

Date: Monday 06 Mar 2023

LONDON (ShareCast) - (Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has met prespecified targets in a phase 2 trial the companies said on Monday.
Positive high-level results from an analysis of the ongoing trial showed Enhertu met the prespecified target for objective response rate and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pre-treated patients.

The trial is evaluating the efficacy and safety of Enhertu in patients with locally advanced, unresectable, or metastatic previously treated, HER2-expressing solid tumours not eligible for curative therapy, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare cancers.

It is already in use for patients with HER2-targetable breast, gastric and lung cancers.

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,172.00p
Change Today -74.00p
% Change -0.60 %
52 Week High 12,370.00
52 Week Low 9,501.00
Volume 1,412,796
Shares Issued 1,550.24m
Market Cap £188,695m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.74% below the market average92.74% below the market average92.74% below the market average92.74% below the market average92.74% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
59.31% above the market average59.31% above the market average59.31% above the market average59.31% above the market average59.31% above the market average
70.37% above the sector average70.37% above the sector average70.37% above the sector average70.37% above the sector average70.37% above the sector average
Income
91.42% below the market average91.42% below the market average91.42% below the market average91.42% below the market average91.42% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
82.31% above the market average82.31% above the market average82.31% above the market average82.31% above the market average82.31% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 8
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 15-May-2024

Time Volume / Share Price
16:26 0 @ 12,178.00p
16:26 0 @ 12,178.00p
16:21 0 @ 12,190.00p
16:21 0 @ 12,190.00p
16:17 0 @ 12,200.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page